Cartesian Looks To Chart The Way For CAR-T In Autoimmune Disease

A Phase IIb trial testing Cartesian’s autologous mRNA-engineered CAR-T therapy for the treatment of generalized myasthenia gravis (MG) met the primary endpoint.

autoimmune disease
Cartesian announced clinical trial data for a CAR-T in autoimmune disease. • Source: Shutterstock

Cartesian Therapeutics, Inc. has positive data from a Phase IIb trial testing Descartes-08, an autologous mRNA-engineered chimeric antigen receptor T-cell (CAR-T) therapy directed against the B-cell maturation antigen (BCMA) in patients with generalized myasthenia gravis (MG), positioning the company at the forefront of development of CAR-T therapeutics for autoimmune disease.

Key Takeaways
  • A Phase IIb trial testing Descartes-08, an autologous mRNA-engineered CAR-T therapy in patients with generalized myasthenia gravis (MG), was positive.

The trial represents the first placebo-controlled study of a CAR-T cell therapy in autoimmune disease to the best of Cartesian’s...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Immunological

More from Therapy Areas

GSK’s Blenrep US Setback Could Go From Bad To Worse

 

With a US approval any time soon now looking unlikely, analysts are revising Blenrep’s peak sales guidance downwards.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.